CPO-107

DB18492InvestigationalProtein Based Therapies

CPO-107 is a CD20-CD47 bispecific fusion protein.

Mechanism: Pharmacologically active on B-lymphocyte antigen CD20 and Leukocyte surface antigen CD47
Curator reviewed
Code names: CPO-107 · JMT601

Resolves to

Compound

Targets

What you can answer from here — as of July 09, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with CPO-107, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.